Polygenic scores (PGSs) have emerged as promising tools for complex trait risk prediction.
The application of these scores to pharmacogenomics provides new opportunities to …

Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy resulting in the
production of abnormal lymphoid precursor cells. Occurring in B-cell and T-cell subtypes …

Osteonecrosis is a significant toxicity of acute lymphoblastic leukemia (ALL) therapy. In
retrospective analyses, superior event-free survival was noted among affected adolescents …

A majority of children and young adults with acute lymphoblastic leukemia (ALL) are cured
with contemporary multiagent chemotherapy regimens. The high rate of survival is largely …

Acute lymphoblastic leukemia (ALL) is a heterogenous hematological malignancy
representing 25% of all cancers in children less than 15 years of age. Significant …

With recent prospective clinical trials that used paediatric regimens with multiple doses of
pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly …

Asparaginase therapy is a vital agent in the treatment of acute lymphoblastic leukemia
(ALL), with increasing evidence of its high importance in high-risk ALL populations …

Background/objectives Although thromboembolism (TE) is a serious complication in patients
with acute lymphoblastic leukemia (ALL), thromboprophylaxis is not commonly used due to …

Osteonecrosis is a serious complication of antileukemic therapy associated with severe pain
and reduced mobility, ultimately leading to joint destruction and significant long-term …

Abstract Purpose of Review This review aims to help oncologists who predominantly treat
adults better understand and manage asparaginase associated toxicities and prevent …